Hand Dermatitis

Researchers are evaluating camoteskimab, a drug being studied in adults with moderate-to-severe atopic dermatitis. This phase 2b study is multicenter, randomized, double-blind, and placebo-controlled, aiming to assess the drug's effects compared to placebo. Participants include those who have not been treated before and those who have had an inadequate response to previous biologic therapies. The study has two parts: Part 1 is a 24-week period where participants are randomly assigned to one of four groups receiving one of three doses of camoteskimab or a placebo, all given by subcutaneous injection. In Part 2, an extension period, all participants will receive camoteskimab. This design allows researchers to compare the drug doses with placebo initially and then provide treatment to all participants. Participants will be involved for at least 24 weeks in the placebo-controlled phase and beyond during the extension. They will undergo assessments including the Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), and peak itch ratings. Researchers will measure changes in eczema severity, itch intensity, and skin condition over time. Safety and adherence will be monitored throughout the study period to evaluate the drug's effects and tolerability.

Researchers are evaluating SHR-1894, a drug administered by single subcutaneous injection, in healthy adults aged 18 to 45 years. This Phase I clinical trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-1894. The study compares different doses of SHR-1894 injection with a placebo injection under controlled conditions. Participants will be randomly assigned to receive either SHR-1894 injection at varying doses or a placebo injection. Both participants and researchers will be unaware of the assigned treatment to ensure unbiased results. The study includes a follow-up period lasting up to 85 days to monitor effects and drug behavior in the body. During the trial, participants will undergo physical exams, vital sign checks, ECGs, chest X-rays, abdominal ultrasounds, and laboratory tests before and after treatment. Researchers will track any adverse events, measure drug concentrations in the blood over time, and assess immune responses. The total participation time covers screening, dosing, and monitoring visits spread across nearly three months.

Researchers are evaluating real-world treatment patterns and clinical outcomes in patients aged 12 years and older with moderate-to-severe atopic dermatitis who are receiving abrocitinib. The study aims to describe patient demographics and baseline characteristics over a 12-month observation period to better understand how abrocitinib is used in usual clinical practice conditions. Participants will be newly prescribed abrocitinib as decided by their physician during routine care. The study does not involve experimental treatments but observes how abrocitinib is used and its effects in everyday settings. There are no comparator groups or placebo treatments since this is an observational study. During the 12-month observation, researchers will track improvements in eczema severity using measures like the Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), and patient-reported outcomes such as the Peak Pruritus Numerical Rating Scale (PP-NRS). Data on treatment duration, quality of life, and symptom changes will also be collected. Patients' progress will be monitored at multiple time points including weeks 2, 4, 12, 16, 24, and 52.

Researchers are evaluating how the combined use of transcranial direct current stimulation (tDCS) and action observation therapy (AOT) may help improve hand motor recovery in people who have had a stroke. This study focuses on understanding the brain mechanisms involved when these two therapies are used together, as both have shown promise separately for stroke rehabilitation. The trial is a randomised controlled study involving 60 participants with chronic stroke from Sabah, Malaysia. Participants will be randomly assigned to one of three groups: one group will receive active anodal tDCS with AOT, another will receive sham (placebo) tDCS with AOT, and the third will receive active tDCS alone. The treatment involves 10 sessions over two weeks in a clinic, where tDCS is applied for 20 minutes and AOT or control videos are watched for 30 minutes during each session. After the clinic phase, participants will continue home-based AOT or control video practice for 30 minutes a day, five days a week, for eight weeks. During the 10-week study, participants will attend outpatient sessions monitored by a physiotherapist to ensure proper participation and will be assessed at baseline, after two weeks, and at the end of 10 weeks. Researchers will measure changes in brain motor pathways using motor evoked potentials (MEPs) and evaluate clinical hand function using standard tests. Participant activity levels will be tracked using a perceived exertion scale, and safety and compliance will be closely monitored throughout the study.

Researchers are investigating chronic hand eczema (CHE) and atopic dermatitis (AD) in adults with moderate to severe forms of these conditions, as well as in healthy volunteers. The study aims to characterize differences in skin features and molecular markers over time using noninvasive methods. It also evaluates how disease severity relates to lifestyle, occupation, smoking, and quality of life. Participants include adults with moderate to severe CHE, those with moderate to severe AD, and healthy adults. The study uses noninvasive imaging and molecular techniques to assess skin changes and collects samples such as plasma, serum, blood, stool, and skin materials for long-term analysis. An optional genetic analysis called tape stripping may be performed on CHE participants. During the 12-month study, participants undergo assessments of skin morphology and molecular signatures, alongside evaluations of quality of life and disease impact. Samples are stored for up to 10 years to support further research. Participants are monitored for changes in skin condition and lifestyle effects, with data compared across the groups including healthy controls.

Researchers are collecting various samples from adults with different inflammatory skin diseases as well as healthy volunteers to better understand these conditions. The study aims to analyze these samples using methods like biomarker testing and gene expression profiling to gain molecular insights into skin diseases such as acne, atopic dermatitis, chronic hand eczema, hidradenitis suppurativa, palmoplantar pustulosis, and psoriasis. Participants include healthy adults and adults diagnosed with specific skin conditions aged 18 years or older, with acne subjects limited to ages 18 to 45 years. The study involves collecting blood, oral, hair, skin (using tape strips, biopsies, or scrapings), skin surface materials, drainage fluid, and stool samples. These samples will be used for various analyses to explore biomarkers and gene expression. During the study, participants will provide the different biological samples on Day 1, which will be analyzed for untargeted biomarkers and gene expression profiles. The researchers will monitor these molecular markers to understand skin disease characteristics. Participants must consent to the procedures and be available for the study duration. The study is observational, with no treatment given, and focuses on sample collection and molecular data gathering.

Researchers are studying how treatments for atopic dermatitis, a chronic skin condition often accompanied by bacterial infections, affect the types and amounts of bacteria on the skin. This research focuses on both patients with moderate to severe eczema aged 2 to 50 years and healthy volunteers aged 18 to 50 years without eczema. The study aims to better understand how antimicrobial treatments impact the skin microbiome over time. Participants are randomly assigned to different treatment groups that include various antibiotic regimens such as cephalexin, doxycycline at different doses, and trimethoprim/sulfamethoxazole, as well as placebo capsules and dilute bleach baths. Treatments are given orally or as topical baths over periods ranging from 14 to 56 days. Some participants may receive combined treatments of antibiotics and bleach baths, and others may receive placebo treatments. The study involves a longitudinal design with repeated sampling and follow-up visits. During the one-year participation, all volunteers and patients undergo regular visits for physical exams, medical history reviews, and collection of skin and microbiome samples, including possible skin biopsies. The research team monitors changes in the skin bacteria and evaluates treatment effects using clinical assessments like the SCORAD score. Safety and treatment responses are tracked, and healthy volunteers might have an additional follow-up visit after one year. The primary outcome is to characterize changes in the skin microbiome within two weeks of treatment.

Researchers are studying the skin compatibility of cosmetic products by testing for potential irritants and allergic reactions. This trial focuses on adults with skin conditions who undergo patch testing to identify whether cosmetics cause skin irritation or allergies. The study is led by Insel Gruppe AG, University Hospital Bern, and aims to assess the safety of new or reformulated cosmetics for people with dermatitis. Participants will receive a patch test where a cosmetic product is applied to their back to observe skin reactions. This procedure helps to detect allergic or irritant responses. The study does not use a control or placebo group and does not involve masking or blinding. During the study, participants will be monitored for positive skin reactions to the patch test over a period of four weeks. Researchers will track the number of patients showing allergic or irritant responses. Participants must avoid certain medications and skin treatments before testing and will be followed to ensure accurate results and safety throughout the trial.

Atopic dermatitis (AD) is a common, long-lasting inflammatory skin condition in children that causes itching and skin lesions, affecting quality of life. This research evaluates a hypnosis program as a possible new therapy to help manage AD symptoms. The study is a pilot randomized controlled trial designed to test the feasibility of hypnosis in children and teenagers with AD, addressing the need for alternative treatments due to challenges like chronicity and treatment costs. Participants will be divided into two groups: one receiving a therapeutic education program alone, and the other receiving the same program combined with two standardized hypnosis sessions using a "superhero costume" technique. The hypnosis group will also practice self-hypnosis at home using an audio recording to reinforce the sessions. The study aims to assess how well this hypnosis program can be integrated into care for AD. During the study, researchers will monitor patient recruitment over 24 months and evaluate compliance with self-hypnosis at 1, 3, and 6 months after joining the study. They will also track patient satisfaction, dropout rates, parents' impressions, improvements to the hypnosis program, and overall effectiveness at these intervals. The trial involves children aged 8 to 17 with mild to severe AD, and participation will include follow-up assessments at scheduled times.

Researchers are investigating the immune characteristics of chronic hand eczema in adults aged 18 to 65 years. This study aims to reveal new insights into the disease by comparing different types of chronic hand eczema, including endogenous forms like atopic dermatitis and idiopathic subtypes such as pompholyx and hyperkeratotic eczema, as well as exogenous forms such as allergic and irritant eczema. The goal is to identify immune cell groups and molecular markers that could lead to personalized treatments. The study uses advanced techniques called spatial transcriptomics and single-cell spatial proteomics to analyze skin biopsy samples from affected areas. Patients diagnosed with chronic hand eczema will have their disease severity assessed through validated scores and patch tests, followed by skin biopsies to confirm the diagnosis. These biopsies will undergo detailed genetic and protein analysis to map the immune landscape of the eczema. Participants will be involved for an average of two years during which the main measurement will be the spatial proteomics analysis of their skin samples. Throughout the study, severity scores like HECSI, DLQI, and itch scales will be used to evaluate the condition. The research team will monitor the immune profiles to understand disease mechanisms and potential targets for therapy, with no masking or blinding involved.